On the stock market since 2021, it operates in the world of health and science. It has 485 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
An average decline of 14% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Business Quality: Profit power and business quality trail similar companies in the sector.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
angles, checked one by one.
The 5 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
An investor who bought at the very peak is down 99% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $170.2M a year. A small number, but proof the product has real buyers.
A loss of $312.8M against $170.2M in annual sales. And on top of that, sales fell from the year before.
At the current pace of spending, the cash lasts about 1.4 years. After that, the company needs to find new money.
On our five-subject report card, DNA sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: DNA is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.